Belimumab Approved for Active Lupus Nephritis in Adults
In a randomized trial, belimumab (Benlysta) vs placebo added to standard therapy demonstrated superiority in achieving the primary efficacy renal response at 104 weeks.
Lupus Nephritis
Mycophenolate Mofetil vs Cyclophosphamide in the Induction Treatment of Lupus Nephritis
Researchers evaluated the efficacy and safety of the induction treatment with mycophenolate mofetil and cyclophosphamide for lupus nephritis.
Low Platelet Distribution Width May Predict Lupus Nephritis
Patients with systematic lupus erythematosus who have a low platelet distribution width (PDW) are more likely to have lupus nephritis than those with a normal or high PDW, a study found.
Voclosporin Granted Priority Review for Lupus Nephritis
The FDA will give Priority Review to the New Drug Application (NDA) of voclosporin (Aurinia Pharmaceuticals) for the treatment of lupus nephritis.
Lack of EULAR/ERA-EDTA Response Predicts Chronic Kidney Disease in Patients With Lupus Nephritis
Researchers evaluated EULAR/ERA-EDTA response to therapy in patients with lupus nephritis.
Belimumab Plus Standard Lupus Nephritis Therapy Improves Renal Responses
Patients with LN who received belimumab in addition to standard therapy experienced a significant 49% decreased risk of renal-related events or death compared with those who received placebo plus standard therapy, a phase 3 study found.
Voclosporin NDA for Lupus Nephritis Submitted to FDA
The New Drug Application (NDA) for voclosporin (Aurinia Pharmaceuticals) has been submitted to the Food and Drug Administration (FDA) for the treatment for lupus nephritis.
Updated EULAR/ERA-EDTA Recommendations for the Management of Lupus Nephritis
The EULAR/ERA-EDTA developed updated recommendations for the management of lupus nephritis.
FDA: Studies Underway to Evaluate Chloroquine for COVID-19
The FDA announced that it is working closely with other government agencies and academic centers to investigate the potential use of chloroquine for the treatment of coronavirus disease 2019 (COVID-19).
Antimalarials May Cut Risk for Type 2 Diabetes in Lupus Patients
T2DM risk reduced by 39 percent for those with high adherence to antimalarial therapy for managing lupus.
-
Loading...
-
Loading...
Next post in Lupus Nephritis
